2011

Schlingensiepen et al.

Transforming growth factor-beta 2 gene silencing with trabedersen (AP 12009) in pancreatic cancer

Cancer Science, doi: 10.1111/j.1349-7006.2011.01917.xhttp://onlinelibrary.wiley.com/doi/10.1111/j.1349-7006.2011.01917.x/abstract

2011

Bogdahn U. et al.

Targeted Therapy for High-Grade Glioma with the TGF-beta2 Inhibitor Trabedersen: Results of a Randomized and Controlled Phase IIb Study

Neuro-Oncology 13, doi: 10.1093/neuonc/noq142http://www.antisense-pharma.com/fileadmin/data_antisense/PDF_Dokumente/Publikationen/Bogdahn_et_all_HGG_Neuro-Oncology_2010.pdf

2010

Schlingensiepen K.-H. et al.

Antisense Nucleic Acids in the Treatment of Malignant Tumors

In: Zeller WJ, zur Hausen H, editors. Oncology: Basics - diagnosis - therapy - developments. Landsberg / Lech: Ecomed, p. IV-20

2008

Schlingensiepen, K.-H. et. al.

Targeted Downregulation of TGF-beta_2 with AP 12009 in Tumor Therapy

From: Cancer Drug Discovery and Development: Transforming Growth Factor-beta in Cancer Therapy, Vol II: Cancer Treatment and Therapy, Chapter 38, pages 635-651, Humana Press Inc.

2008

Schlingensiepen, K.-H. et. al.

Antisense Therapeutics for Tumor Treatment - The TGF-beta_2 Inhibitor AP 12009 in Clinical Development against Malignant Tumors

From: Pancreatic Cancer, Part III: New Treatment Strategies and Outlook, Chapter 16, Pages 137-150, Springer

2007

Hau, P. and Jachimczak P. et. al.

Inhibition of TGF-beta2 with AP 12009 in recurrent malignant glioma: From preclinical to Phase I/II studies

Oligonucleotides 17: 201-212 http://www.liebertonline.com/doi/abs/10.1089/oli.2006.0053

2006

Schlingensiepen, K.-H. et. al.

Targeted tumor therapy with the TGF-beta2 antisense compound AP 12009

Cytokine Growth Factor Reviews 17: 129-139 http://www.sciencedirect.com/science/article/pii/S1359610105001061

2005

Schlingensiepen, R. et. al.

Intracerebral and Intrathecal Infusion of the TGF-beta2-Specific Antisense Phosphorothioate Oligonucleotide AP 12009 in Rabbits and Primates: Toxicology and Safety

Oligonucleotides 15: 94-104http://www.liebertonline.com/doi/abs/10.1089/oli.2005.15.94

2005

Schlingensiepen, R. et. al.

Immunotherapy against malignant tumors with antisense AP 12009: Technology, Target, Therapy

Oncology Journal 07: 24-30http://www.journalonko.de/aktuellview.php?id=1173

1996

Jachimczak, P. et al.

Transforming growth factor-beta-mediated autocrine growth regulation of gliomas as detected with phosphorothioate antisense oligonucleotides

Int J Cancer 65: 332-337http://www3.interscience.wiley.com/cgi-bin/abstract/59720/ABSTRACT

1993

Jachimczak, P. et al.

The effect of transforming growth factor-beta2-specific phosphorothioate-antisense oligodeoxynucleotides in reversing cellular immunosuppression in malignant glioma

J Neurosurg 78: 944-951http://thejns.org/doi/abs/10.3171/jns.1993.78.6.0944

2010

Ikushima, H. & Miyazono, K.

TGFbeta signalling: a complex web in cancer progression

Nature Reviews Cancer 10: 415-424http://www.nature.com/nrc/journal/v10/n6/full/nrc2853.html

2009

Padua D & Massague J.

Roles of TGF-β in metastasis

Cell Res.19 19: 89-102.

2008

Seoane J.

The TGF-β pathway as a therapeutic target in cancer

Clin Transl Oncol. 10: 14-9.

2006

Akhurst, R. J.

Large- and small-molecule inhibitors of transforming growth factor-beta signaling

Curr Op Invest Drugs 7: 513-521